Results per Page:
Fred Hutch Phase 1 Program director, Dr. John Thompson, retires
An immunotherapy champion, Thompson co-led the melanoma clinic for decades
Cigarettes or vapes, pick your poison
From the Fong Lab, Translational Sciences & Therapeutics Division
When it comes to cancer trials, what’s the (end)point?
New endpoint in multiple myeloma could mean faster drug approvals. Are more endpoint tweaks on the way?
Here comes the sun! What’s your skin strategy?
Avoiding sunburn is the first step in preventing deadly skin cancer melanoma
Clinical trials excluding fewer cancer patients with brain ‘mets’
In other news, 1 in 5 people with cancer participate in research studies
Gene specific alternative polyadenylation can reduce tumor growth
From the Bradley Lab, Basic and Public Health Sciences Divisions
Rethinking immunotherapy dosing frequency for better cost, time, and life savings!
From the Bhatia group, Clinical Research Division
Knowing your risk for inherited cancers matters
Take advantage of year-end family gatherings to discuss health history
Retired Oregon cardiologist chose proton therapy for choroidal melanoma treatment
Patient overcomes two cancers in five years
Reducing frequency of immunotherapy dosing could save money and time, keep patients on therapy longer
Study of immune checkpoint inhibitor dosing in patients with advanced skin cancers could help guide long-term treatment plans
Being your own caregiver during cancer
Friends, siblings, support groups and social media can all make a huge difference for patients ‘cancering’ on their own
New therapeutic strategy turns a cancer’s advantage into its downfall
In the lab, researchers use synthetic mRNA to trick tumors into manufacturing cancer-specific poison
Selective stimulation of neoantigen-specific T cells by immunotherapy
From the Riddell Lab, Clinical Research Division
Kent police officer takes charge of his toughest case yet
Garth's eye problems ended up being ocular melanoma.